HomeCompareSYN vs DIVO

SYN vs DIVO: Dividend Comparison 2026

SYN yields 196.08% · DIVO yields 6.62%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SYN wins by $45.6K in total portfolio value
10 years
SYN
SYN
● Live price
196.08%
Share price
$1.02
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.5K
Annual income
$74.42
Full SYN calculator →
DIVO
DIVO
● Live price
6.62%
Share price
$44.00
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.0K
Annual income
$1,008.47
Full DIVO calculator →

Portfolio growth — SYN vs DIVO

📍 SYN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSYNDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SYN + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SYN pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYN
Annual income on $10K today (after 15% tax)
$16,666.67/yr
After 10yr DRIP, annual income (after tax)
$63.26/yr
DIVO
Annual income on $10K today (after 15% tax)
$562.67/yr
After 10yr DRIP, annual income (after tax)
$857.20/yr
At 15% tax rate, DIVO beats the other by $793.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYN + DIVO for your $10,000?

SYN: 50%DIVO: 50%
100% DIVO50/50100% SYN
Portfolio after 10yr
$53.8K
Annual income
$541.45/yr
Blended yield
1.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SYN right now

SYN
Analyst Ratings
5
Buy
2
Hold
Consensus: Buy
Altman Z
-14.5
Piotroski
2/9
DIVO
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYN buys
0
DIVO buys
0
No recent congressional trades found for SYN or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSYNDIVO
Forward yield196.08%6.62%
Annual dividend / share$2.00$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%0%
Portfolio after 10y$76.5K$31.0K
Annual income after 10y$74.42$1,008.47
Total dividends collected$34.4K$8.4K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: SYN vs DIVO ($10,000, DRIP)

YearSYN PortfolioSYN Income/yrDIVO PortfolioDIVO Income/yrGap
1← crossover$20,504$9,803.92$11,362$661.96+$9.1KSYN
2$31,333$9,393.40$12,860$702.91+$18.5KSYN
3$40,234$6,707.62$14,504$743.56+$25.7KSYN
4$47,075$4,024.82$16,303$783.73+$30.8KSYN
5$52,570$2,200.55$18,268$823.31+$34.3KSYN
6$57,399$1,148.35$20,408$862.17+$37.0KSYN
7$62,003$585.89$22,737$900.20+$39.3KSYN
8$66,638$295.74$25,266$937.31+$41.4KSYN
9$71,452$148.53$28,008$973.42+$43.4KSYN
10$76,528$74.42$30,977$1,008.47+$45.6KSYN

SYN vs DIVO: Complete Analysis 2026

SYNStock

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

Full SYN Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this SYN vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYN vs SCHDSYN vs JEPISYN vs OSYN vs KOSYN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.